Clinical Analysis of Alpharadin to be Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology
News Jun 06, 2011
Algeta ASA has announced that an analysis of clinical data from its phase II clinical program with Alpharadin will be presented at the 2011 ASCO Annual Meeting in Chicago, Illinois, USA (3-7 June 2011).
The analysis concluded that the ALP normalization caused by Alpharadin (radium-223) in patients with bone metastases from castration-resistant prostate cancer (CRPC) was associated with a significant improvement in overall survival.
Poster title: Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223.